Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit

摘要

Disclosed is a pharmaceutical formulation in a single unit dosage form, wherein the dosage form comprises: (a) a nucleoside reverse transcriptase inhibitor thereof, and (b) a nucleotide reverse transcriptase inhibitor thereof, wherein the formulation is in the form of a multi-layered tablet or a coated core tablet, and wherein the nucleoside reverse transcriptase inhibitor is provided in a different region of the dosage form to the nucleotide reverse transcriptase inhibitor thereof.